Altarac David 4
4 · Entasis Therapeutics Holdings Inc. · Filed Jan 27, 2020
Insider Transaction Report
Form 4
Altarac David
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-01-23+50,000→ 50,000 totalExercise: $4.94Exp: 2030-01-22→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.